These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

73 related articles for article (PubMed ID: 2770375)

  • 1. [What is the aim of uncontrolled phase IV studies on efficacy?].
    de Abajo FJ; Frías J; Garijo B; Lopo CR
    Med Clin (Barc); 1989 Jun; 93(1):38-9. PubMed ID: 2770375
    [No Abstract]   [Full Text] [Related]  

  • 2. Postmarketing studies of drug efficacy.
    Strom BL; Melmon KL; Miettinen OS
    Arch Intern Med; 1985 Oct; 145(10):1791-4. PubMed ID: 3899034
    [No Abstract]   [Full Text] [Related]  

  • 3. Contraceptive development and clinical trials.
    Fraser IS
    Clin Reprod Fertil; 1986 Feb; 4(1):75-85. PubMed ID: 3708511
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical data gap between phase III clinical trials (pre-marketing) and phase IV (post-marketing) studies: evaluation of etanercept in rheumatoid arthritis.
    Farahani P; Levine M; Gaebel K; Thabane L
    Can J Clin Pharmacol; 2005; 12(3):e254-63. PubMed ID: 16278497
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Importance and challenges of studying marketed drugs: what is a phase IV study? Common clinical research designs, registries, and self-reporting systems.
    Glasser SP; Salas M; Delzell E
    J Clin Pharmacol; 2007 Sep; 47(9):1074-86. PubMed ID: 17766697
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Postmarketing surveillance versus clinical trials: which benefits the patient?
    Lawson DH
    Cardiology; 1994; 85 Suppl 1():18-23. PubMed ID: 7743530
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Pharmacokinetics in phase IV studies for the preview of a therapeutic protocol].
    Favre R; Charbit M; Rinaldi Y; Iliadis A; Cano JP; Carcassonne Y
    Bull Cancer; 1988; 75(6):541-50. PubMed ID: 3416086
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The science of health technology assessment--clinical effectiveness of therapeutic interventions.
    LeLorier J
    Can J Clin Pharmacol; 2001; 8 Suppl A():21A-23A. PubMed ID: 11586374
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Drug safety. Gaps in the safety net.
    Couzin J
    Science; 2005 Jan; 307(5707):196-8. PubMed ID: 15653480
    [No Abstract]   [Full Text] [Related]  

  • 10. [Pre- and post-marketing management of side effects of drugs. Application to antidepressive agents].
    Auriche M
    Therapie; 1988; 43(4):299-306. PubMed ID: 3055408
    [No Abstract]   [Full Text] [Related]  

  • 11. [Sense and nonsense in post-authorization surveillance].
    de Mey C
    Med Klin (Munich); 2000 May; 95(1 Spec No):77-82. PubMed ID: 10851853
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Post-marketing surveillance of drugs: epidemiologic approach].
    Stanulović M; Jakovljević V; Sabo A
    Med Pregl; 1987; 40(11-12):573-7. PubMed ID: 3331415
    [No Abstract]   [Full Text] [Related]  

  • 13. The need for human data: the role of clinical trials and postmarketing surveillance in the safety assessment of macronutrient substitutes.
    Forbes AL
    Regul Toxicol Pharmacol; 1996 Feb; 23(1 Pt 2):S20-1; discussion S31-7. PubMed ID: 8801611
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Food and Drug Administration's use of postmarketing (Phase IV) study requirements: exception to the rule?
    Steenburg C
    Food Drug Law J; 2006; 61(2):295-383. PubMed ID: 16903034
    [No Abstract]   [Full Text] [Related]  

  • 15. Costs of research and patent considerations.
    Vickery BH
    J Androl; 1987; 8(1):S27-32. PubMed ID: 3549653
    [No Abstract]   [Full Text] [Related]  

  • 16. Short patent lives jeopardize drug and patient safety.
    Hondeghem LM; De Clerck F; Camm J
    J Cardiovasc Pharmacol; 2007 Oct; 50(4):353-7. PubMed ID: 18049301
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The role of databases in drug postmarketing surveillance.
    Rodriguez EM; Staffa JA; Graham DJ
    Pharmacoepidemiol Drug Saf; 2001; 10(5):407-10. PubMed ID: 11802586
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [How to assess the risk of drugs?].
    Roujeau JC
    Ann Dermatol Venereol; 1998 Oct; 125(10):673-5. PubMed ID: 9835953
    [No Abstract]   [Full Text] [Related]  

  • 19. Industry reneges on postmarketing trial commitments.
    Bouchie A
    Nat Biotechnol; 2003 Jul; 21(7):718. PubMed ID: 12833074
    [No Abstract]   [Full Text] [Related]  

  • 20. Drug safety and drug efficacy: two sides of the same coin.
    Young RC; Friedman MA; Schilsky RL; Sigal EV
    Clin Cancer Res; 2007 May; 13(9):2533-4. PubMed ID: 17473179
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 4.